Related Experiment Videos
Activation of the complement system by recombinant tissue plasminogen activator
Journal of the American College of Cardiology
|September 1, 1987
Summary
Recombinant tissue plasminogen activator (rt-PA) therapy for heart attacks activates the complement system in vivo. This study shows significant increases in complement components C4a, C3a, and C5a after rt-PA administration.
Area of Science:
- Cardiology
- Immunology
- Biochemistry
Background:
- Recombinant tissue plasminogen activator (rt-PA) is a key thrombolytic agent for acute myocardial infarction.
- Plasmin, generated by rt-PA, is known to activate the complement system in vitro.
- The in vivo effects of rt-PA on complement activation in patients with myocardial infarction require investigation.
Purpose of the Study:
- To test the hypothesis that rt-PA induces in vivo complement activation.
- To quantify changes in complement components C4a, C3a, and C5a following rt-PA administration in acute myocardial infarction patients.
Main Methods:
- Study involved 12 patients with acute myocardial infarction.
- Six patients received rt-PA for complete coronary occlusion; six controls had patent arteries without rt-PA.
- Blood samples were collected before and after rt-PA administration (or arteriography in controls) to measure C4a, C3a, and C5a levels.
Main Results:
- Baseline complement levels were similar between rt-PA treated and control groups.
- After rt-PA administration, but before reperfusion, significant increases were observed in C4a (p < 0.01), C3a (p < 0.05), and C5a (p < 0.05).
- Control patients showed no significant complement activation.
Conclusions:
- rt-PA administration in acute myocardial infarction patients triggers a significant in vivo activation of the complement system.
- This complement activation occurs independently of reperfusion.
- Findings suggest a potential immunomodulatory role for rt-PA beyond thrombolysis.